Most searches for SS-31 side effects hit vendor pages that say "well tolerated" and stop. There is an actual record. It is built on injection site reactions, a failed myopathy trial, and 168 weeks of follow-up in 8 patients.
The short answer. SS-31: Injection site reactions are the most commonly reported adverse event, at roughly 50–70% of treated patients.
- The approved population is Barth syndrome at 30 kg or more, not healthy adults.
- The longest published continuous exposure is 168 weeks in 8 patients.
- MMPOWER-3 is the largest randomized safety set, and it missed both primary endpoints.
SS-31 is elamipretide. The FDA approved it in September 2025. The label covers Barth syndrome only. Injection site reactions are the main reported side effect. Long-term data rests on 8 patients over 168 weeks. Nobody has studied it in healthy adults.
What the SS-31 safety record actually contains
SS-31 is elamipretide. The FDA granted it accelerated approval as Forzinity in September 2025, for Barth syndrome, in patients weighing 30 kg or more. Shirley's 2025 approval review in Drugs sets out that history.
That approval matters for this question. It means a regulator reviewed a safety dataset and an adverse-event list exists. Almost nothing else sold as a research peptide can say that.
The dominant finding is unglamorous. The drug goes under the skin, and the skin objects. Redness, itching, swelling and pain at the injection site are the events reported most often, at rates running around 50–70% of treated patients in the published trials.
Elamipretide was generally well tolerated, with injection site reactions the most commonly reported adverse events.
Stealth BioTherapeutics, TAZPOWER 168-week open-label extension, Genetics in Medicine, 2024- A dominant local reaction. Injection site events, not systemic ones, drive the reported adverse-event tables.
- One randomized comparison at scale. MMPOWER-3 ran 24 weeks in primary mitochondrial myopathy.
- One long extension. TAZPOWER's open-label arm reached 168 weeks in 8 Barth patients.
- A sick population. Everyone in these trials had a mitochondrial disease. None were healthy volunteers taking it for aging.
The approval story itself is covered in full on the SS-31 Barth syndrome FDA page.
How big is the safety database?
Smaller than the word "approved" suggests, and that is not a criticism of the drug. Barth syndrome affects roughly 1 in 300,000–400,000 male births. You cannot enroll thousands of people who do not exist.
The wider development program is larger. Across its trials, elamipretide exposure has been reported on the order of 3,500 subjects. But most of that exposure is short, and the longest continuous run on record is the Barth extension.
| Study | What it ran | What it adds to safety |
|---|---|---|
| TAZPOWER (Barth syndrome) | 28-week randomized, then open-label to 168 weeks | Longest exposure on record, 8 patients |
| MMPOWER-3 (mitochondrial myopathy) | 24-week randomized | Largest randomized set; missed both primary endpoints |
| MMPOWER-3 genotype post hoc (2024) | Reanalysis of existing data | No new exposure; subgroup signal only |
| Aged mice (Aging Cell, 2025) | 8 weeks of treatment in old mice | No human safety content at all |
Treatment with elamipretide did not meet the primary endpoints of change in 6-minute walk test distance and fatigue score.
Karaa et al., MMPOWER-3, Neurology, 2023MMPOWER-3 failed on efficacy. It still did the safety work, because a trial that misses its endpoint still counts adverse events. That is the largest controlled block of SS-31 tolerability data anyone has.
What the safety record does not contain
This is the part the vendor pages skip. The known adverse-event profile describes a specific use, in a specific population, for a specific length of time. Step outside that and the record goes quiet.
- No healthy adults on long-term use. The trials enrolled people with mitochondrial disease. Side effects in an otherwise healthy person are not characterized.
- No children under the weight cutoff. The approval sits at 30 kg or more for a reason.
- Nothing past 168 weeks. And that window covers 8 people. It is the ceiling of published human experience, not a clean bill of health.
- No data on stacking. Combination use with other research peptides has not been studied in any trial.
- No data on grey-market material. Trials used pharmaceutical product made under GMP. That is not what ships in a research vial.
"Well tolerated in Barth syndrome over 168 weeks in 8 patients" is a true sentence. "Safe" is a different sentence, and nobody has earned it yet.
Is SS-31 safe for anti-aging use?
Unknown. No human trial has given SS-31 to healthy adults for aging, so there is no adverse-event table for that use. Human longevity trials of this compound number zero.
The longevity pitch rests on animals. Mitchell and colleagues published an aged-mouse study in Aging Cell in 2025. Elamipretide improved cardiac and skeletal muscle function in old mice. It did not shift the tissue epigenetic or transcriptomic age markers the authors measured.
That is a functional result in mice, not a safety result in people. The jump from one to the other is the whole marketing argument, and it is unsupported. The mechanism, which runs through cardiolipin in the inner mitochondrial membrane, is set out on the cardiolipin mechanism page, and the broader claim set on the SS-31 benefits page.
Risks that come from the vial, not the molecule
A four-amino-acid peptide in a lyophilized vial carries risks that have nothing to do with the published trials. These are the ones a buyer can actually check.
- Identity and purity. A third-party certificate of analysis, with a batch number matching your vial, is the only document that speaks to what is in it. How to read a COA.
- Sterility. Research vials are not sterile injectables. Local reactions in the trials came from a GMP product; a contaminated one is a different problem entirely.
- Handling and storage. Degradation is invisible. Storage temperature and reconstitution both change what ends up in the solution.
- Legal status. Research-use material is not an approved medicine. Peptide legality covers the framing.
The full development picture, including what the trials measured and missed, is on the SS-31 complete guide.
What to know now
- Injection site reactions are the most commonly reported adverse event, at roughly 50–70% of treated patients.
- The approved population is Barth syndrome at 30 kg or more, not healthy adults.
- The longest published continuous exposure is 168 weeks in 8 patients.
- MMPOWER-3 is the largest randomized safety set, and it missed both primary endpoints.
- Human trials of SS-31 for aging number zero; that case rests on aged mice.
- An approved drug's safety record does not transfer to a research vial of the same molecule.
What we're watching
Stealth BioTherapeutics elamipretide (Forzinity) Barth syndrome approval coverage
Frequently asked questions
What are the most common SS-31 side effects?
Injection site reactions. The drug is given under the skin, and redness, itching, swelling and pain at the site are the events reported most often in the published trials, at rates around 50–70% of treated patients. Systemic events have not dominated the reported tables.
Is SS-31 safe long term?
The longest published continuous human exposure is 168 weeks, in 8 Barth syndrome patients in the TAZPOWER open-label extension. That is the ceiling of the record. Nothing has been published beyond it, so long-term safety past that window is simply unmeasured.
Does SS-31 have side effects in healthy people?
Unknown. Every participant in the trials had a mitochondrial disease. No study has given elamipretide to healthy adults for aging or performance, so there is no adverse-event profile for that use at all.
Did the failed MMPOWER-3 trial raise safety problems?
MMPOWER-3 failed on efficacy, not on safety. Karaa and colleagues reported in Neurology in 2023 that it did not meet its primary endpoints of 6-minute walk distance and fatigue score. A later 2024 post hoc analysis looked at genotype subgroups. The trial still contributed the largest randomized block of tolerability data in the program.
Is a research vial of SS-31 the same as the approved drug?
No. The FDA approved a specific product, made under pharmaceutical manufacturing rules, for one rare disease. A research vial is not that product and carries no approval. Its purity and sterility are only as good as the third-party certificate of analysis that comes with the batch.
References
- Shirley, M. (2025). Elamipretide: First Approval. Drugs, 86(3), 377–383. https://doi.org/10.1007/s40265-025-02269-8
- Karaa, A., Haas, R., Goldstein, A., Vockley, J., & Cohen, B. (2023). Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: The MMPOWER-3 randomized clinical trial. Neurology. https://doi.org/10.1212/WNL.0000000000207402
- Stealth BioTherapeutics. (2024). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in Medicine. https://doi.org/10.1016/j.gim.2024.101138
- Karaa, A., Bertini, E., Carelli, V., et al. (2024). Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: A post hoc analysis of the MMPOWER-3 trial. Orphanet Journal of Rare Diseases, 19(1), 431. https://doi.org/10.1186/s13023-024-03421-5
- Tung, C., Varzideh, F., Farroni, E., et al. (2025). Elamipretide: A review of its structure, mechanism of action, and therapeutic potential. International Journal of Molecular Sciences, 26(3), 944. https://doi.org/10.3390/ijms26030944
- Mitchell, W., Pharaoh, G., Tyshkovskiy, A., et al. (2025). The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age. Aging Cell, 24(6), e70026. https://doi.org/10.1111/acel.70026
- Clarke, S. L. N., Bowron, A., Gonzalez, I. L., et al. (2013). Barth syndrome. Orphanet Journal of Rare Diseases, 8, 23. https://doi.org/10.1186/1750-1172-8-23
- Obi, C., Smith, A. T., Hughes, G. J., & Adeboye, A. A. (2022). Targeting mitochondrial dysfunction with elamipretide. Heart Failure Reviews, 27(5), 1925–1932. https://doi.org/10.1007/s10741-021-10199-2
